Assessment of the effectiveness of L-carnitine and curcumin in the treatment of non-alcoholic fatty liver

Assessment of the effectiveness of L-carnitine and curcumin in the treatment of non-alcoholic fatty liver in patients aged 5 to 15 years old

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210412050944N2

Enrollment

Registered

2022-10-10

Start date

2022-09-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Metabolic disorder, unspecified

Interventions

Intervention 1: Intervention group 1: For a group of 33 patients, L-carnitine tablets are prescribed at a dose of 50 milligrams per kilogram of body weight in one day (Karen Pharmaceutical Company, Ir

training on how to take the drug, side effects, beneficial effects, how to treat and the mechanism of action of L-carnitine in the body, and how to evaluate the child's treatment. The duration of trai

training on how to take the drug, side effects, beneficial effects, how to treat and the mechanism of action of Sina curcumin nanomicelle soaftgel in the body, and how to evaluate the child's treatmen

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Patients who are between 5 to 15 years old. Patients who have increased their liver enzymes more than 40 units per liter. Patients who have been diagnosed with fatty liver in ultrasound. Patients who have been diagnosed with non-alcoholic fatty liver disease by pediatric gastroenterology specialist. Patients who parents consent to participate in this plan.

Exclusion criteria

Exclusion criteria: Patients who suffering from viral hepatitis. Patients who suffering from diabetes. Patients who have taken drugs affecting liver tests in the last 2 months. Patients who suffering from hemochromatosis. Patients who suffering from cirrhosis. Patients who who suffering from addicted to alcohol Patients who suffering from infectious diseases. Patients who suffering from hypothyroidism. Patients who are allergic to curcumin or L-carnitine. Patients who suffering from hypothyroidism. Patients who have not completed the medication for 3 months

Design outcomes

Primary

Measure	Time frame
Percentage of children with non-alcoholic fatty liver. Timepoint: Before the intervention and 3 months after the administration of L-carnitine and curcumin in the intervention groups. Method of measurement: Ultrasonography and biochemical tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Janani

Qazvin University of Medical Sciences

somayeh_janani1361@yahoo.com+98 28 3332 8709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026